Results 91 to 100 of about 585,966 (213)

Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis

ImmunoTargets and Therapy, 2021
Laura C Arneson,1,* Kristen J Carroll,1,* Eric M Ruderman2 1Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 2Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School ...
Arneson LC, Carroll KJ, Ruderman EM
doaj  

Myelin Impairment and Regeneration in the Central Nervous System: Molecular Mechanisms, Diseases, and Prospective Therapeutic Targets

MedComm, Volume 7, Issue 10, October 2026.
Proper myelin formation is crucial for normal neural circuit function, while myelin deficiency can lead to neural circuit dysfunction and cognitive decline, notably in Alzheimer's disease and other central nervous system demyelinating disorders. This review summarizes central myelin's structure and function, demyelination biomarkers and pathological ...
Lihong Huang, Peng Cheng, Guangdong Liu, Yang Xiang, Zhen Hong, Weidong Le   +5 more
wiley   +1 more source

Bruton Tyrosine Kinase Inhibitors

The Cancer Journal, 2019
Abstract Bruton tyrosine kinase (BTK) is a nonreceptor tyrosine kinase that plays a central role in the signal transduction of the B-cell antigen receptor and other cell surface receptors, both in normal and malignant B lymphocytes. B-cell antigen receptor signaling is activated in secondary lymphatic organs and drives the proliferation of ...
openaire   +3 more sources

To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy

European Journal of Haematology, Volume 117, Issue 4, Page 750-766, October 2026.
ABSTRACT Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch‐and‐wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Giovanna Cutrona, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Franco Fais, Antonino Neri, Manlio Ferrarini, Valter Gattei, Fortunato Morabito, Massimo Gentile   +16 more
wiley   +1 more source

pharmacological application of tyrosine kinase inhibitors in certain malinancies

, 2019
The use of targeted therapy to inhibit tyrosine kinases, as a form of cancer chemotherapy is one of the major medical advances in the past decade. Tyrosine kinases activate many signal transduction cascades by adding a phosphate group to proteins and ...
Peslin, Pavel
core  

Ets-2 is a target for an Akt (protein kinase B)/Jun N-terminal kinase signaling pathway in macrophages of motheaten-viable mutant mice [PDF]

, 2000
The transcription factor ets-2 was phosphorylated at residue threonine 72 in a colony-stimulating factor 1 (CSF-1)- and mitogen-activated protein kinase-independent manner in macrophages isolated from motheaten-viable (me-v) mice.
Forsthoefel, David, Ostrowski, M C, Hartman, M, Schaffner, A E, Smith, James L., Hume, D A, Smith, J L, Ostrowski, Michael C., Wei, G, Hofmeister, Joseph K., Hofmeister, J K, Schaffner, Alicia E., Wei, Guo, Hume, David A., Hartman, Matthew, Hartman, Matthew Hartman, Forsthoefel, D   +16 more
core   +1 more source

B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292

ImmunoTargets and Therapy, 2014
Jon E Arnason,1 Jennifer R Brown21Beth Israel Deaconess Medical Center, 2CLL Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USAAbstract: Chronic lymphocytic leukemia (CLL) is the most common ...
Arnason JE, Brown JR
doaj  

Treatment of relapsed/refractory chronic lymphocytic leukemia with Zanubrutinib after progressing on other BTK inhibitors

Leukemia Research Reports
Chronic Lymphocytic Leukemia (CLL) is the most common type of leukemia in the US, representing approximately 1.1% of all new cancers diagnosed. Most patients with CLL can be monitored without treatment, and the indicated treatment options include a CD20 ...
Nkolika Nwankwo, Aswanth Reddy, Swarup Kumar, Maha Zafar   +3 more
doaj   +1 more source

Targeting Bruton Tyrosine Kinase: A novel strategy in the treatment of B-cell lymphomas

Forum of Clinical Oncology, 2017
In normal B-cells, Bruton tyrosine kinase (Btk), a non-receptor tyrosine kinase involved in B-cell receptor (BCR) signalling, is essential for cell survival and maturation. Not surprisingly, Btk is also implicated in the pathogenesis of B-cell lymphomas,
Sklavenitis-Pistofidis R., Koletsa T., Lazaridou A., Goulas A.   +3 more
doaj   +1 more source

Extranodal Marginal Zone Lymphoma: Integrating Etiology, Microenvironment, and Genetics Into Clinical Decision‐Making

European Journal of Haematology, Volume 117, Issue 4, Page 849-863, October 2026.
ABSTRACT Extranodal marginal zone lymphoma (EMZL) represents a unique paradigm among indolent B‐cell neoplasms, in which lymphomagenesis is frequently driven by chronic antigenic stimulation within tissue‐specific microenvironments. Persistent infectious or autoimmune triggers promote the development of ectopic lymphoid tissue and sustain B‐cell ...
Mamdouh Skafi, Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Marco Fiorillo, Eugenio Lucia, Graziella D'Arrigo, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Giovanni Tripepi, Fortunato Morabito, Massimo Gentile   +15 more
wiley   +1 more source